Candel Therapeutics announced its Q3 2026 financial results, reporting a net loss of $21.9 million and cash reserves of $203.1 million, sufficient to fund operations into Q2 2028. The company is progressing with its Biologics License Application (BLA) submission for aglatimagene, a prostate cancer immunotherapy, planned for mid-2027 after ongoing FDA discussions. Clinical trial data presented at SITC 2026 demonstrated systemic immune activation and promising survival outcomes in prostate cancer, non-small cell lung cancer, and recurrent high-grade glioma. Candel also strengthened its leadership team to support regulatory and commercial readiness ahead of potential product launches.
Candel Therapeutics Q3 2026 financial results provide context for readers. For those tracking the health sector, 23 of 150 US stocks rose and 124 fell on Pluang as of Nov 13, 2026 04:11 WIB. Notable movers include MRNA at USD 230.95 with a 7.13% decrease, Butterfly Network at USD 6.64 down 7.00%, and Recursion Pharmaceuticals at USD 3.34 down 6.96%.
Siemens reported earnings per share of $1.62 and revenue of $26.28 billion, both exceeding analyst expectations. The company saw record orders and double-digit revenue growth in its smart infrastructure and digital industries units, prompting it to r...
ASUS has introduced a broad ecosystem of AI-ready hardware and software designed for gamers, creators, developers, and enterprises. The ASUS Agent Computer initiative enables users to deploy AI locally, in the cloud, or via hybrid models, offering co...
The global cosmetic peptide synthesis market is projected to grow from $274 million in 2027 to $354.85 million by 2032, with a CAGR of 5.34%. Growth is fueled by rising demand for advanced anti-aging skincare ingredients, increased use of peptide-bas...
Cisco is set to report its fiscal Q1 2027 earnings with a focus on cloud growth and AI demand. Analysts expect revenue around $18.1 billion, operating income of $6.5 billion, and earnings per share of $1.33, reflecting strong year-over-year growth. T...
BASF has agreed to sell its global mining solutions business to SNF, a specialty chemical company based in France, following a strategic review of BASF's Performance Chemicals division. The deal includes BASF's mining chemicals portfolio, production ...
